Respiratory Tuberculosis (Pulmonary TB) – A Complete Patient Guide

Overview

Respiratory tuberculosis (RTB), more commonly called pulmonary tuberculosis, is an infectious disease caused by the bacterium Mycobacterium tuberculosis. The bacteria primarily settle in the lungs, where they trigger an inflammatory response that can damage lung tissue and impair breathing.

While TB can affect anyone, certain groups are disproportionately impacted:

• People living in crowded or poorly ventilated settings (e.g., prisons, shelters, refugee camps)
• Individuals with weakened immune systems—such as those with HIV, diabetes, or on immunosuppressive therapy
• Older adults (≥65 years) whose immune response naturally declines
• People with a history of previous TB infection or close contact with an active case

According to the World Health Organization (WHO), an estimated 10 million new cases of active TB occurred worldwide in 2022, and about **85 %** of these were pulmonary (respiratory) forms. In the United States, the Centers for Disease Control and Prevention (CDC) reported **≈8,200** cases of active TB in 2022, with **≈81 %** involving the lungs. The disease remains a leading cause of death from a single infectious agent—surpassed only by COVID‑19 in recent years.

Symptoms

Symptoms of respiratory TB develop gradually over weeks to months. Early disease may be mild, making it easy to miss without a high index of suspicion.

Most common respiratory signs

• Persistent cough lasting >2 weeks, often worsening at night
• Hemoptysis (coughing up blood or blood‑tinged sputum)
• Chest pain—typically a dull, aching discomfort that may increase with deep breathing
• Shortness of breath (dyspnea), especially on exertion

Systemic (body‑wide) manifestations

• Unexplained fever (often low‑grade, 38 °C/100.4 °F), frequently worse in the evenings
• Night sweats that soak clothing or bedding
• Progressive weight loss and loss of appetite
• Fatigue or generalized weakness
• Occasional headache or dizziness if the disease spreads to the central nervous system (rare)

Less common but important clues

• Swollen lymph nodes (especially cervical)
• Joint pain or arthritis‑like symptoms if TB spreads to bones (Pott’s disease)
• Abdominal discomfort (when TB involves the gastrointestinal tract)

Because many of these signs overlap with other respiratory illnesses (e.g., pneumonia, chronic bronchitis), laboratory testing is essential for a definitive diagnosis.

Causes and Risk Factors

Primary cause

RTB results from inhalation of aerosolized droplets that contain M. tuberculosis. The bacteria can remain suspended in the air for several hours, especially in enclosed spaces with poor ventilation.

Key risk factors

• Close contact with an infectious person—especially household members or coworkers in crowded settings.
• HIV infection—immune suppression increases the risk of reactivation by up to 20‑fold.
• Diabetes mellitus—hyperglycemia impairs macrophage function.
• Smoking—damages airway epithelium and diminishes local immune defenses.
• Malnutrition—reduces the body’s ability to mount an effective cellular immune response.
• Substance abuse (especially alcohol and intravenous drugs)—linked to poor adherence to treatment.
• Age—elderly patients have a higher risk of reactivation due to immunosenescence.
• Travel or residence in high‑TB‑incidence countries (e.g., India, China, South Africa, Philippines).

Diagnosis

Accurate diagnosis combines clinical evaluation with specific laboratory and imaging studies.

1. Medical History & Physical Exam

• Document duration of cough, fever pattern, weight change, and exposure history.
• Physical exam may reveal crackles, reduced breath sounds, or enlarged lymph nodes.

2. Microbiologic Tests

• Sputum smear microscopy—acid‑fast bacilli (AFB) staining (Ziehl‑Neelsen or auramine). Provides rapid (24‑48 h) results but lower sensitivity (~60 %).
• Sputum culture—gold standard; grows on solid (Lowenstein‑Jensen) or liquid (MGIT) medium. Takes 2‑6 weeks but detects drug‑resistance patterns.
• NAAT (Nucleic Acid Amplification Test)—e.g., GeneXpert MTB/RIF. Provides results within hours, identifies rifampin resistance, and is endorsed by WHO and CDC.
• Rapid molecular testing for additional drug‑resistance mutations (e.g., line‑probe assay).

3. Radiologic Evaluation

• Chest X‑ray—most widely used; typical findings include upper‑lobe infiltrates, cavitations, and nodular lesions.
• Chest CT scan—offers higher resolution; useful for atypical presentations or when X‑ray is inconclusive.

4. Additional Tests (if indicated)

• Interferon‑γ release assays (IGRAs)—blood tests (e.g., QuantiFERON‑TB) that detect latent infection; not used for active disease but helpful in screening.
• HIV testing—recommended for all patients with suspected TB.
• Baseline liver function tests before initiating hepatotoxic drugs.

Diagnosis is confirmed when at least one of the following is positive: AFB smear, culture, or NAAT for M. tuberculosis, together with compatible clinical & radiographic findings.

Treatment Options

Effective therapy requires a combination of antibiotics taken for a minimum of six months. Treatment regimens are tailored to drug‑susceptibility results and patient factors.

First‑line anti‑TB drugs (standard 4‑drug regimen)

1. Isoniazid (INH) – bactericidal; administered daily 300 mg.
2. Rifampin (RIF) – potent sterilizing agent; 600 mg daily.
3. Pyrazinamide (PZA) – active in acidic environments; 1,500 mg daily (often given 2‑times per day).
4. Ethambutol (EMB) – prevents resistance; 1,200 mg daily.

These drugs are taken for an intensive phase of **2 months**, followed by a continuation phase of **4 months** with INH + RIF only, provided the strain is drug‑sensitive.

Drug‑resistant TB

• Multidrug‑resistant TB (MDR‑TB)—resistant to INH and RIF. Requires second‑line agents (fluoroquinolones, aminoglycosides, linezolid, bedaquiline). Treatment often lasts 18‑24 months.
• Extensively drug‑resistant TB (XDR‑TB)—MDR‑TB plus resistance to any fluoroquinolone and at least one second‑line injectable. Managed with newer drugs (delamanid, pretomanid) in specialist centers.

Adjunctive Therapies

• Corticosteroids—recommended for TB meningitis and pericardial TB; occasionally used for severe pulmonary disease with extensive inflammation.
• Nutritional support—high‑protein, calorie‑dense diets improve outcomes.
• Smoking cessation programs—reduce relapse risk.

Lifestyle & Adherence Strategies

• Use **directly observed therapy (DOT)**—a health worker watches each dose to ensure compliance.
• Set daily alarms or pill organizers.
• Report side effects promptly (e.g., vision changes from ethambutol, jaundice from INH/RIF).

Living with Respiratory Tuberculosis

Successful management goes beyond medication; it involves practical daily habits.

Medication Management

• Take drugs on an empty stomach (usually 1 hour before or 2 hours after meals) for optimal absorption.
• Separate INH from calcium‑rich foods or antacids to avoid reduced efficacy.
• Maintain a medication diary; share it with your healthcare team at each visit.

Infection Control at Home

• Stay in a well‑ventilated room; keep windows open when feasible.
• Wear a surgical mask when you cough; replace it daily.
• Cover your mouth with a tissue or elbow when coughing; dispose of tissues immediately.
• Household members should be screened and, if indicated, offered preventive therapy (isoniazid or rifampin prophylaxis).

Nutrition & Hydration

• Consume 2‑3 L of water per day to aid drug metabolism and prevent kidney stones (especially with pyrazinamide).
• Include protein‑rich foods (lean meat, beans, dairy) and vitamin‑rich fruits/vegetables.
• Limit alcohol, which can worsen hepatotoxicity.

Physical Activity

• Light aerobic exercise (walking, stretching) improves lung capacity and mood.
• Avoid high‑intensity workouts if you experience significant dyspnea or fever.

Mental Health

Stigma and the long treatment course can cause anxiety or depression. Seek counseling, join support groups, or talk to a mental‑health professional. Many national TB programs provide free psychosocial assistance.

Prevention

• BCG vaccination—provides partial protection against severe forms of TB in children; effectiveness against pulmonary TB in adults varies.
• Screen high‑risk populations—regular testing for healthcare workers, prisoners, migrants, and people living with HIV.
• Use of UV germicidal lamps in congregate settings can reduce airborne bacilli.
• Prompt treatment of active cases—reduces community transmission; each untreated case can infect 10‑15 others per year.
• Environmental controls—adequate ventilation, negative‑pressure isolation rooms for hospitalized patients.

Complications

If left untreated or inadequately treated, respiratory TB can lead to serious, sometimes irreversible consequences:

• Cavitary lung disease—permanent holes that predispose to chronic infection and hemoptysis.
• Bronchiectasis—dilated airways causing recurrent sputum production and infections.
• Fibrosis and restrictive lung disease—reduced lung volumes and chronic breathlessness.
• Pleural effusion or empyema—fluid buildup that may require drainage.
• Miliary TB—disseminated spread via bloodstream; can involve liver, spleen, bone marrow, and brain.
• Drug‑induced hepatotoxicity—necessitates medication adjustments.
• Multi‑drug resistance—arises from incomplete or irregular therapy, leading to prolonged illness and higher mortality.

When to Seek Emergency Care

References

1. World Health Organization. Global Tuberculosis Report 2023. WHO; 2023.
2. Centers for Disease Control and Prevention. Tuberculosis (TB) — Basic Information. CDC; 2024.
3. Mayo Clinic. Tuberculosis Symptoms and Causes. Updated 2023.
4. Cleveland Clinic. Tuberculosis (TB). 2024.
5. National Institute of Allergy and Infectious Diseases (NIAID). Tuberculosis. 2022.
6. World Health Organization. WHO Consolidated Guidelines on Tuberculosis: Module 4 – Drug‑Resistant TB Treatment. 2021.